Biotech News

Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026

Precision BioSciences (DTIL)Precision BioSciences2026-06-25 13:46 ESTEarnings

DURHAM, N.C. --(BUSINESS WIRE)--Apr. 30, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial

Open original release

Related news

DTILPrecision BioSciences2026-06-25 13:46 EST

Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026

DTILPrecision BioSciences2026-06-25 13:46 EST

Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026

DTILPrecision BioSciences2026-06-25 13:46 EST

Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting

DTILPrecision BioSciences2026-06-25 13:46 EST

Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program

DTILPrecision BioSciences2026-06-25 13:46 EST

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update

DTILPrecision BioSciences2026-06-25 13:46 EST

Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference

DTILPrecision BioSciences2026-06-25 13:46 EST

Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries

DTILPrecision BioSciences2026-06-25 13:46 EST

Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update

DTILPrecision BioSciences2026-06-25 13:46 EST

Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study

DTILPrecision BioSciences2026-06-25 13:46 EST

Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting

View all latest news

Precision BioSciences

Precision BioSciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

DTILPrecision BioSciences2026-06-26 11:24 EST

Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026

DTILPrecision BioSciences2026-06-26 11:24 EST

Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026

DTILPrecision BioSciences2026-06-26 11:24 EST

Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting

DTILPrecision BioSciences2026-06-26 11:24 EST

Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program

DTILPrecision BioSciences2026-06-26 11:24 EST

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States